BUZZ - Spyre Therapeutics shares tumble due to $350 million stock offering
路透社2026/10/06 11:26On October 6, Spyre Therapeutics (SYRE.O) shares fell 4.1% to $88.90 in pre-market trading after the company priced a $350 million follow-on offering. The biotechnology firm announced late Monday that it was issuing approximately 4.1 million shares at $85 per share, an 8.3% discount to its last closing price. The company plans to use the net proceeds to advance its programs in gastroenterology, rheumatology, and dermatology, as well as to move a new project—SPY072—into later-stage development for the chronic skin disease hidradenitis suppurativa, among other uses. Jefferies, TD Cowen, Leerink, and Stifel are acting as joint book-running managers for the offering. On September 30, Merck’s (MRK.N) tulisokibart achieved success in a dermatology clinical trial, after which SYRE shares climbed about 5%. Analysts noted that the trial data supports SYRE's experimental candidate targeting the same signaling pathway. Headquartered in Waltham, Massachusetts, SYRE had around 88.2 million shares outstanding prior to the offering. As of Monday’s close, the stock had risen 183% year-to-date. According to LSEG data, 16 of 17 analysts rate the stock a “strong buy” or “buy,” with one analyst rating it “hold.” The median price target is $123. (For the convenience of non-English speakers, Reuters provides automated translations of its reports. Automated translations may contain errors or lack necessary context; Reuters makes no guarantee regarding the accuracy of machine translations and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation.)
October 6 - ** Spyre Therapeutics (SYRE.O) shares fell 4.1% in premarket trading to $88.90 after the company priced a subsequent $350 million financing
** The biotechnology company announced late Monday (link) that it is offering approximately 4.1 million shares at $85 each, an 8.3% discount to the last closing price
** The company plans to use the net proceeds to advance its projects in gastroenterology, rheumatology, and dermatology, and to move forward with a new project—advancing SPY072 to late-stage development for the chronic skin disease “hidradenitis suppurativa,” among other uses
** Jefferies, TD Cowen, Leerink, and Stifel served as joint bookrunners
** On September 30, Merck (MRK.N)’s drug tulisokibart succeeded in a dermatology clinical trial (link), after which SYRE shares rose roughly 5%; analysts said the data supports SYRE's experimental candidate targeting the same pathway
** SYRE, headquartered in Waltham, Massachusetts, had about 88.2 million shares outstanding before the offering
** As of Monday’s close, the stock has risen 183% year-to-date
** According to LSEG data, out of 17 analysts, 16 give the stock a “strong buy” or “buy” rating, 1 rates it “hold”; the median price target is $123
(To assist non-native English speakers, Reuters automates the translation of its reports into several other languages. Because automated translation may be faulty or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters assumes no liability for any damage or loss caused by the use of automated translation functionality.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Australia's Kelsian shares rise as asset sale triggers Morningstar's cautious optimism
Latest developments on October 7th – Kelsian Group (KLS.AX) shares briefly rose 1% to A$3.93 before narrowing gains to 0.3% by midday in Sydney. Morningstar holds a positive view on the transport operator’s recently announced A$150 million (US$104.76 million) sale of travel assets in mid-September. The investment research firm noted that this divestment relieves the transportation and travel operator from reliance on discretionary-spending businesses such as resorts, cruises, and tours. It also stated that the sale enables management to focus more on core operations and moderately reduces capital intensity. However, Morningstar pointed out that the sale means profits from the marine segment will still be "discretionary in nature." It added that the sale will leave the company’s earnings mainly dependent on its US interstate coach business, which is characterized by short-term contracts without cost-adjustment mechanisms and serves highly volatile sectors such as technology, oil, and gas. Year to date, the share price is down 8.2%. (US$1 = A$1.4318) (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be inaccurate or may not completely reflect the required context; Reuters does not guarantee the accuracy of translated texts, which are provided solely for reader convenience. Reuters is not responsible for any harm or loss arising from the use of automatic translation.)
JPMorgan raises Gilead Sciences' target price to $170.
BUZZ - Australian winemaker Treasury Wine recovers early losses, Jefferies believes its troubles in the US are easing
October 7th - Treasury Wine Estates (TWE.AX) shares recovered a 1.8% loss in afternoon trading and were basically flat. Jefferies maintained a "Hold" rating on TWE and an AUD 6 target price, stating that although excess inventory and rising costs in the US market are limiting upside potential, TWE’s underperformance relative to the broader market has been narrowing. The brokerage expects a 1.2% increase in EBIT for fiscal year 2027 and notes that the US wine market is showing moderate growth in the higher price segment. Jefferies mentioned that the price segment below $20 still faces significant challenges and emphasized that low-priced wines continue to face pressure. The brokerage pointed out that competitor Constellation Brands’ (STZ.N) wine and spirits business saw organic sales increase by 17.2% in the second quarter, with sales to retailers up by 10.2%. TWE shares have risen 6.1% year-to-date. (For the convenience of non-English speakers, Reuters offers automated translations of its report into a number of other languages. Automated translation may contain errors or may not capture the intended context, and Reuters does not guarantee the accuracy of this text. It is provided only for convenience, and Reuters is not liable for any damage or loss caused by the use of automated translation.)
Bitcoin price falls below 84,000 dollars, oil prices and the US dollar rise
Crypto prices
More
